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Abstract
Understanding the causal relationship between intervention and outcome is at the heart
of most research in the health sciences, and a variety of statistical methods have been
developed to address causality. However, noncompliance with treatment assignment is a
key source of complication for causal inference. Estimation of causal effects is likely to be
compounded by the presence of noncompliance in both treatment arms of clinical trials
where the intention-to-treat (ITT) analysis produces a biased estimator for the true causal
estimate even under homogeneous treatment effects assumption. Principal stratification
method has been developed to address such posttreatment complications by stratifying
the population into partially latent classes (principal strata) based on potential values
observed after randomization (e.g. noncompliance) under each of the levels of randomized
intervention. The present work combines the two strategies of model selection and principal
stratification with a novel application to a real data from a trial conducted to ascertain
whether or not unopposed oestrogen (hormone replacement therapy - HRT) reduced the
risk of further cardiac events in postmenopausal women who survive a first myocardial
infarction. The causal model links the resulting two marginal prediction models with a
user-defined sensitivity parameter which is a function of the correlation between the two
compliance behaviours. The method’s key assumption of conditional prediction is verified
for our data via sensitivity analysis comparing results of causal estimates using different sets
of predictors of compliance. We adjust for noncompliance in both treatment arms under a
Bayesian framework to produce causal risk ratio estimates for each principal stratum. The
results suggested better efficacy for HRT among those who would comply with it compared
to those who would comply with either HRT or placebo: compliance with HRT treatment
only and with either treatment allocation would reduce the risk for death (reinfarction) by
47%(25%) and 13%(60%) respectively.
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Abstract. Understanding the causal relationship between intervention and outcome is at
the heart of most research in the health sciences, and a variety of statistical methods have
been developed to address causality. However, noncompliance with treatment assignment
is a key source of complication for causal inference. Estimation of causal effects is likely
to be compounded by the presence of noncompliance in both treatment arms of clinical
trials where the intention-to-treat (ITT) analysis produces a biased estimator for the true
causal estimate even under homogeneous treatment effects assumption. Principal stratifica-
tion method has been developed to address such posttreatment complications by stratifying
the population into partially latent classes (principal strata) based on potential values ob-
served after randomization (e.g. noncompliance) under each of the levels of randomized
intervention. The present work combines the two strategies of model selection and principal
stratification with a novel application to a real data from a trial conducted to ascertain
whether or not unopposed oestrogen (hormone replacement therapy - HRT) reduced the
risk of further cardiac events in postmenopausal women who survive a first myocardial
infarction. The causal model links the resulting two marginal prediction models with a
user-defined sensitivity parameter which is a function of the correlation between the two
compliance behaviours. The method’s key assumption of conditional prediction is verified
for our data via sensitivity analysis comparing results of causal estimates using different sets
of predictors of compliance. We adjust for noncompliance in both treatment arms under a
Bayesian framework to produce causal risk ratio estimates for each principal stratum. The
results suggested better efficacy for HRT among those who would comply with it compared
to those who would comply with either HRT or placebo: compliance with HRT treatment
only and with either treatment allocation would reduce the risk for death (reinfarction) by
47%(25%) and 13%(60%) respectively.
Paper presented at the 2nd Strathmore International Mathematics Conference (SIMC 2013), 12 - 16 August 2013,
Strathmore University, Nairobi, Kenya.
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I. Introduction
Valid causal inference is a central motivation in the analysis of data from randomised controlled
trials when comparing two or more interventions. Effective randomization of subjects between
the treatment groups plays a key role in permitting such statistical comparison [22, 19]. How-
ever, the presence of intermediate variables in the intervention-outcome causal pathway is likely
to complicate estimation of causal effects by introducing selection bias since they often manifest
themselves as non-random phenomena [41, 24]. Noncompliance with treatment assignment one
such phenomenon which may often manifests itself as treatment discontinuation, switching or
subject dropout from the study. Intention-to-treat (ITT) is the standard analysis for estimating
causal effects under perfect compliance with treatment assignment. By comparing treatment
groups as assigned, the ITT analysis preserves the baseline comparability between treatment
groups. However, using ITT results in presence of treatment noncompliance are likely to under-
estimate the treatment efficacy by mixing the effects of treatment compliers and non-compliers
[43]. Since noncompliance mostly manifests itself as a non-random phenomenon, it is a challenge
adjusting for its corresponding informative characteristics.
Applying standard regression methods to adjust for intermediate variables produce
estimates which lack causal interpretation [29]. One reason for failure in causal analysis is be-
cause such methods make the very strong but often implausible assumption of unmeasured
confounders between the intermediate variable and outcome. In the presence of noncompliance,
per-protocol and as-treated analyses are commonly used to supplement ITT in evaluating ef-
ficacy [42, 20]. But these post-hoc analyses lack the benefits of randomization, for example,
selection bias in these methods may be evident in different compliance behaviour in different
treatment arms. Efron and Feldman [9] in their seminal work used compliance as a covari-
ate in a regression adjustment for a placebo-controlled clinical trial evaluating the efficacy of
Cholestyramine in lowering serum cholesterol levels towards reducing the risk of coronary heart
disease. However, their method has been criticized for the implicit strong assumption of com-
parability in compliance between the active treatment and placebo arms [1, 3]. In the presence
of selectivity effects, many methods have been developed to account for noncompliance in more
than one treatment arm.
Frangakis and Rubin [11] developed the principal stratification as a general framework
to adjust for intermediate variables observed post-randomization. The method basically strat-
ifies the population into partially latent classes (principal strata) based on potential values of
posttreatment variable, like a noncompliance status. Principal strata comprise units having the
same values of the intermediate potential outcomes and are not affected by treatment assign-
ment hence retains the tenets of randomization and so provide valid and well-defined causal
effect estimates for selected subgroup/strata.
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Principal stratification is a flexible method for causal modelling which may be extended
to adjusting for noncompliance in more than one treatment arm. But owing to the latent nature
of principal strata, causal inference using the method often requires making structural assump-
tions to allow parameter identification. According to Cole and Frangakis [6], causal estimates
are generally identifiable under three sufficient assumptions: exchangeability (no unmeasured
confounders), positivity (existence of a non-zero probability to receive treatment) and consis-
tency (relating observed data to counterfactual data). In the presence of more than one active
treatment, a joint analysis may provide additional analytical insights than pairwise efficacy com-
parisons [4]. In general, comparing more than one active treatment compounds the challenge of
identification of causal estimates due to possible multiple forms/degrees of noncompliance with
treatment assignment [30, 21].
Crucial to parameter identification under principal stratification method is selection of
good baseline covariates which are predictive of the intermediate status (e.g. noncompliance).
The implicit challenge of model selection is not only a statistical problem [17] but may be
compounded when applied to intermediate variables occurring on the causal pathway and ob-
served post-randomisation. An efficient selection of plausible predictors of intermediate variables
can be used to effectively address identification problem of causal estimands by reducing bias
in addition to relaxing implicit causal assumptions [20]. From a clinical perspective, adequate
knowledge about predictors of treatment compliance may be a valuable tool to inform treatment
decisions. Shrinkage principle is a common strategy of reducing regression coefficients to im-
prove the quality of predictions through bias-variance tradeoff so as to produce stable models in
the presence of many predictors [34]. For example, Tibshirani [38] introduced the least absolute
shrinkage and selection operator (Lasso) as an efficient model selection method which performs
the twin tasks of variable selection and regression coefficient estimation simultaneously.
To adjust for noncompliance with treatment assignment, Roy et al. [30] proposed a
principal stratification framework for trials to compare two active treatments using baseline
covariates to address identification problem. Long et al. [21] also proposed a likelihood esti-
mation method to provide point causal estimands for a three-armed trial by using Bayesian
methods to model the arm-specific compliances directly while treating the principal compliance
status as missing. And by using Bayesian methods in a potential outcome framework, Zigler
and Belin [44] recently used a key covariate predictive of compliance for causal effect estimation
in an active-control trial. On the other hand, Fischer et al. [10] proposed a structural mean
modelling approach using baseline covariates predictive of compliance in each arm to obtain
compliance-adjusted efficacy in a randomized controlled trial comparing two-active treatments.
Central to the application of Roy et al. [30] model is the conditional prediction assump-
tion that potential outcomes are statistically independent of the set of covariates predictive of
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compliance given a stratum and treatment assignment. In the presence of many recorded base-
line covariates and given this defining assumption, this underscores the crucial role of selecting
efficient and meaningful predictors of compliance with treatment assignment for each trial arm.
Using a Bayesian approach, the present work modifies and extends the principal stratification
method of Roy et al. [30] to integrate optimal model selection procedures using plausible sep-
arate predictors of compliance in each arm and apply it to analyze survival data in terms of
causal risk ratio estimates for each principal stratum of the Esprit study.
The rest of the paper is organized as follows: Section 2 describes the motivating data
from the Esprit study. In Section 3, we describe the relevant causal modeling assumptions.
Section 4 provide a brief outline of the methods of analysis by first presenting model selection
predicting arm-specific compliance followed by the causal model framework linking the marginal
compliance models and the resulting Bayesian inference. Section 5 present an application and
results from analysis of the Esprit data. Finally, Section 6 presents a broad discussion.
II. Motivating data: The Esprit study
The onset of menopause is often characterized by diminishing production of oestrogen hormones
due to a decline in ovarian function whose unpleasant symptoms (e.g. vasomotor, insomnia,
fatigue and depression) can impact negatively on the body leading to low quality of life among
such women for the better part of the last third of their lives [27]. Hormone replacement therapy
(HRT) is a treatment for oestrogen-deficiency symptoms which is mainly administered in two
broad forms depending on whether a woman has her uterus intact or not: unopposed oestrogen
(oestrogen taken by itself) for those who have had hysterectomy (removal of the uterus) or
oestrogen with progestin for the non-hysterectomized. The addition of progestin is meant to
counteract the effects of estrogen on the uterus like endometrial cancer. Although observational
studies conducted in the last quarter of last Century showed benefits of HRT in lowering rates
of coronary heart disease [12], follow-up clinical trials failed to confirm such beneficial effects
among postmenopausal women.
The oEStrogen in the Prevention of ReiInfarction Trial (Esprit) study was one of the
trials whose ITT results revealed no HRT benefit among postmenopausal women [5]. Esprit was
a two-armed placebo-controlled double blind clinical trial conducted to ascertain whether or
not unopposed oestrogen reduces the risk of further cardiac events in postmenopausal women
aged between 50 − 69 years who survived a first myocardial infarction in England and Wales.
The study comprised a total of 1017 subjects: 513 and 504 women were randomized to HRT
treatment and placebo arms respectively and monitored over 24 months period. The primary
outcomes were cardiac deaths and all-cause mortality or reinfarction. Although ITT analysis
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of the data has been previously published, however the analysis took no account of compliance
data which we use in this paper to estimate true causal effects.
III. Notation and assumptions
We consider a parallel two-armed clinical trial set up. Let Z ∈ {0, 1} denote a randomization
indicator: Z = 1 indicate randomization to the new treatment and Z = 0 indicates randomiza-
tion to control. In our application, 1 (Z = 1) and 0 (Z = 0) will represent randomization to
HRT tablets and placebo treatment respectively. We define Y ∈ {0, 1} to be the outcome of
interest (e.g. death). Also let A ∈ {0, 1} denote compliance with assigned treatment. For the
Esprit study we define compliance as actual taking of assigned treatment up to a day before
experiencing event of interest (death/reinfarction) or end of study, whichever occurred first.
Although this all-or-nothing compliance definition may appear restrictive, it was considered
adequate and plausible since any potential treatment switches are assumed to occur soon af-
ter randomization and HRT tablets are presumed to have no carryover effects, i.e. assuming
no residual effect of treatment once a subject is classified a non-complier. We note that each
subject has two potential compliance levels A0 and A1 (compliance with placebo and HRT treat-
ment respectively) and two potential outcomes Y0 and Y1 (outcome under placebo and HRT
treatment respectively). But the observed compliance and outcomes are respectively given by
A=ZA1 + (1− Z)A0 and Y =ZY1 + (1− Z)Y0.
Analysis under the principal stratification formulation utilizes baseline covariates X
to modify the standard assumptions (a)-(e) for causal modelling [18, 2] together with a new
assumption (f):
(a) Randomization: Z ⊥ {Y0, Y1, A0, A1, X}, i.e. ignorable treatment assignment assumption.
(b) Stable unit-treatment value assumption (SUTVA), i.e. no interference between treatment
units.
(c) Treatment access restriction: which posits no treatment switches among subjects.
(d) Exclusion restriction: Pr(Y1|AZ , X) = Pr(Y0|AZ , X), i.e. treatment assignment has no
effect on outcome except only through treatment received (knowledge of treatment assign-
ment alone has no effect on outcome).
(e) Monotonicity: Pr(A1 = 1|A0 = 1, X) ≥ Pr(A1 = 1|A0 = 0, X), i.e. the probability of
compliance with treatment assigned by Z = 1 is higher among those who would comply
with treatment assigned by Z=0, compared to those who would not.
(f) Conditional prediction: Y ⊥ X|S,Z, i.e potential outcome is statistically independent
(ignorable) of the set of covariates predictive of compliance for a given principal stratum
and treatment assignment.
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Any switching of treatment is assumed to have occurred soon after randomization such
that a subject is assumed to have completely taken HRT or placebo treatment. Assuming no
other form of treatment interruptions among patients and no carryover effects of treatment,
the all-or-nothing compliance definition above may be considered plausible with respect to the
exclusion restriction assumption. The monotonicity assumption as applied here helps tighten
the bounds of causal effects, i.e. ensures compliance type is observable when Z 6= A [4, 30, 37].
In addition to the basic monotonicity assumption (no treatment defiers), the ‘extended’ mono-
tonicity assumption posits similar compliance behaviour for both treatment arms. Plausibility
of the ‘extended’ version of monotonicity assumption for the Esprit study may be discerned
from the fact that there was no preference for one treatment over the other, i.e compliance with
HRT treatment would be more prevalent among those who would comply with placebo. In our
application, this assumption is reflected through a user-defined positive correlation (sensitivity
parameter φ) between A0 and A1.
The conditional prediction assumption (f) is crucial for parameter identification in the
Roy et al. [30] model. The assumption underscores an integral component of the method which
involves selecting suitable predictors of compliance. The first part of this paper will address
this challenge through a comprehensive model selection of the Esprit study to obtain optimal
arm-specific predictors compliance. We will use penalized maximum likelihood (shrinkage) pro-
cedures to select plausible separate predictors of compliance for HRT treatment and placebo
arms. Although this is an untestable assumption, we will compare results from different sets of
predictors as a form of sensitivity analysis.
Each subject is assumed to belong to one of four basic principal strata defined by unique
combinations of (A0, A1) where the principal strata comprise the set S={(0, 0),(1, 0),(0, 1),(1, 1)}.
The causal inference of interest (Section IV.2) will be to seek the joint distributions [(Y0, Y1)|S=
s] ∀ s ∈ S which provides principal effects of interest for each stratum.
IV. Methods for analysis
IV.1. Compliance prediction models and validation
We use the logistic models to predict compliance to treatment allocation for each arm separately
given a selected set of predictors of compliance x0 =1 and x1, . . . ,xn:
logit [µj(x)]=
(
n∑
i=0
γjixi
)
, j=0, 1, (1)
where µj(x) is the probability of compliance with allocated treatment j given a set of covariates
X: the estimated probabilities of complying with arm-specific treatment allocation may then
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be obtained using
µˆj(x)=
[
1 + exp
(
−
n∑
i=0
γˆjixi
)]−1
, j=0, 1, (2)
where γ represent the log odds ratio estimates of compliance.
How the two compliance behaviours are correlated is a crucial issue. Following Roy
et al. [30], we define a non-negative sensitivity parameter φ as a function of the correlation ρ
between compliances to treatment allocation (0/1): if µˆ0(x) > µˆ1(x) then
φ = ρ
√
¯ˆµ0(x)[1− ¯ˆµ1(x)]
¯ˆµ1(x)[1− ¯ˆµ0(x)]
. (3)
The compliance models for each treatment arm provided by Equations (1) and (2) may
be obtained through comprehensive model selection for predictive covariates, i.e. selecting both
clinically sensible and statistically concise predictors of compliance with treatment assignment
for each trial arm. With many covariates, the classical stepwise model selection procedures are
likely to produce suboptimal prediction models [39, 13]. In comparison, penalized maximum
likelihood methods have been shown to perform relatively better in selecting optimal predictors
[15]. But a selected statistical prediction model also needs validation to evaluate its predictive
ability, for example, external validation enables assessment of the performance of prediction in
new data [34, 32]. But in the absence of further data, bootstrap validation provides reliable
results by allowing calculation of predicted probabilities from a model which can be compared
with the actually observed outcomes [8].
Percentage of optimism and both calibration and discrimination indices are among the
most effective and commonly used measures of validation performance [14]. While calibration
is a reliability measure of how well the model predictions compare with the observed outcomes,
discrimination refers to the ability of the model to distinguish between subjects with positive or
negative outcomes (e.g. the ability of a model to distinguish compliers with treatment allocation
from non-compliers). Calibration is often quantified in practice by the calibration slope [7]
obtainable from the validation plot which is a plot of observed probabilities against the predicted
probabilities. On the other hand, discrimination is commonly measured using the concordance
c-statistic as widely expressed in terms of the Somers rank correlation [33]: Dxy = 2(c − 0.5).
This is a measure of the difference between concordance and discordance probabilities [13], such
that c= 0.5 (1) implies random predictions (perfect discriminations). We can readily discern
that larger values of calibration and discrimination (concordance) indicate better prediction
and such models should indicate lower percentage of optimism.
IV.2. Causal model joining the marginal compliance models
The main causal inference of interest is obtainable from the joint distributions [(Y0, Y1)|S =
s]. Following Roy et al. [30], the joint probability distribution of compliance to the standard
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treatment 0 and compliance to new treatment 1 is a function of the arm-specific marginal
compliance probabilities and φ and can be estimated for a given value of φ. We however note
that φ is unknown, in general. Specifically if U(x) = min{1, µˆ1(x)µˆ0(x)} then Roy et al. [30] showed
that the joint probabilities are given by
µˆ11(x) = Pr(A0 = 1|X)P (A1 = 1|A0 = 1, X)
= µˆ0(x)µˆ1(x) + φµˆ0(x)[U(x)−µˆ1(x)],
µˆ01(x) = Pr(A0 = 0|X)P (A1 = 1|A0 = 0, X)
= µˆ1(x)− µˆ0(x)µˆ1(x)− φµˆ0(x)[U(x)− µˆ1(x)],
µˆ10(x) = Pr(A0 = 1|X)P (A1 = 0|A0 = 1, X)
= µˆ0(x)− µˆ0(x)µˆ1(x)− φµˆ0(x)[U(x)− µˆ1(x)],
µˆ00(x) = Pr(A0 = 0|X)P (A1 = 0|A0 = 0, X)
= 1−µˆ0(x)−µˆ1(x) + µˆ0(x)µˆ1(x) + φµˆ0(x)[U(x)−µˆ1(x)],
(4)
where X is the set of covariates predictive of compliance in both arms and A1(A0) is an indicator
of compliance to HRT treatment (placebo) and µˆij(x) denote the probability of being in the
compliance subgroup ij (i.e. estimated proportion of compliance per stratum).
Following the principal stratification framework developed by Frangakis and Rubin [11],
the possible values of A0 and A1 define a stratification factor S for the population of patients.
For a defined outcome variable Y (mortality/reinfarction for the Esprit study), let Y0 and
Y1 refer to potential outcomes under placebo and HRT treatments respectively. There are four
possible realizations of (Y0, Y1) at each level of S (for example $11 =Pr[Y0 =1, Y1 =1]). The joint
distribution of potential outcomes (Y0, Y1) for each stratum S, f(Y0, Y1|S,$) may be assumed
to be multinomial with probabilities $(S) = Pr(Y0 = y0, Y1 = y1|S = s). And by the exclusion
restriction, the expression for stratum S=(0, 0) differs from the others: $10(0, 0)=$01(0, 0)=0.
After reparameterizing in terms of pi (probability of experiencing event, e.g. death or
myocardial reinfarction) and β=f(γ, φ)) (log odds ratio of compliance for specified sensitivity),
Roy et al. showed that the observed-data likelihood is
L(pi, β|Y,A,Z,X)=
3∑
s=0
[piS=sZ ]
Y [1− piS=sZ ]1−Y Pr(S=s|X,β)G(s,A, Z), (5)
where piS=sZ is the probability that observed Y =1, given S=s and allocation to arm Z, and
G(s,A, Z) =I(s=0){1−A}+ I(s=1){A(1− Z) + (1−A)Z}
+ I(s=2){AZ + (1−A)(1− Z)}+ I(s=3)A.
Now Y and A are observed values; e.g. A = A1 (A0) if allocated to active treatment
(placebo). We can decompose the expression (5) for each stratum:
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L(pi, β|Y =1, A=1, Z = 1, X) = pis=(0,1)1 Pr (S=(0, 1)|X,β)
+ pi
s=,(1,1)
1 Pr (S=(1, 1)|X,β) ,
L(pi, β|Y = 0, A=1, Z=1, X) =[1− pis=(0,1)1 ] Pr (S=(0, 1)|X,β)
+ [1− pis=(1,1)1 ] Pr (S=(1, 1)|X,β) ,
L(pi, β|Y = 1, A=0, Z=1, X) =pis=(0,0)1 Pr (S=(0, 0)|X,β)
+ pi
s=(1,0)
1 Pr (S=(1, 0)|X,β) ,
L(pi, β|Y = 0, A=0, Z=1, X) = [1− pis=(0,0)1 ] Pr (S=(0, 0)|X,β)
+[1− pis=(1,0)1 ] Pr (S=(1, 0)|X,β) ,
L(pi, β|Y = 1, A=1, Z=0, X) = pis=(1,0)0 Pr (S=(1, 0)|X,β)
+ pi
s=(1,1)
0 Pr (S=(1, 1)|X,β) ,
L(pi, β|Y = 0, A=1, Z=0, X) = [1− pis=(1,0)0 ] Pr (S=(1, 0)|X,β)
+ [1− pis=(1,1)0 ] Pr (S=(1, 1)|X,β) ,
L(pi, β|Y = 1, A=0, Z=0, X) = pis=(0,0)0 Pr (S=(0, 0)|X,β)
+ pi
s=(0,1)
0 Pr (S=(0, 1)|X,β) ,
L(pi, β|Y = 0, A=0, Z=0, X) = [1− pis=(0,0)0 ] Pr (S=(0, 0)|X,β)
+ [1− pis=(0,1)0 ] Pr (S=(0, 1)|X,β) .
(6)
By the exclusion restriction pi
s=(0,0)
1 = pi
s=(0,0)
0 , i.e.the risk of experiencing event of
interest (e.g. death) is independent of the arm of allocation among the people who would
comply with neither allocation. Writing
pi1 = pi
s=(0,1)
1 , pi2 =pi
s=(1,1)
1 , pi3 =pi
s=(0,0)
1 , pi4 =pi
s=(1,0)
1 ,
pi5 =pi
s=(1,0)
0 , pi6 =pi
s=(1,1)
0 , pi7 =pi
s=(0,1)
0 ,
(7)
we obtain 7 parameters captured by pi from the likelihoods above using logistic models:
Pr[Y =1|A=1, Z=1]=pi1µ01 + pi2µ11,
Pr[Y =1|A=0, Z=1]=pi3µ00 + pi4µ10,
Pr[Y =1|A=1, Z=0]=pi5µ10 + pi6µ11,
Pr[Y =1|A=0, Z=0]=pi3µ00 + pi7µ01.
(8)
We then obtain the stratum-specific relative risks for experiencing an event (death/reinfarction)
as
τ11 =
pi
s=(1,1)
1
pi
s=(1,1)
0
=
pˆi2
pˆi6
, τ01 =
pi
s=(0,1)
1
pi
s=(0,1)
0
=
pˆi1
pˆi7
, τ10 =
pi
s=(1,0)
1
pi
s=(1,0)
0
=
pˆi4
pˆi5
. (9)
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The τij above provides the desired principal (causal) effects in terms of causal risk ratios
obtained as medians of posterior relative risks of event (death or reinfarction) for each stratum
defined by compliance type:
(i) τ11: causal risk ratio of event due to compliance with HRT treatment relative to placebo
among the subgroup of patients who would comply with either treatment allocation, i.e.
S=(1, 1),
(ii) τ01: causal risk ratio of event due to compliance with HRT treatment only among women
who would comply if allocated to it, i.e. S=(0, 1) and
(iii) τ10: causal risk ratio of event due to compliance with placebo treatment only among the
subgroup who would comply if allocated to it, i.e. S=(1, 0).
The parameters above (Equation 9) can be estimated using Bayesian methods with
suitable priors. Using uninformative (flat) priors pi∼U(0, 1), for example, may be satisfactory
for our analyses given the likelihood of a typical trial data to dominate such priors and the fact
that randomized trials are principally designed to be conclusive [16].
To extend the methods which adjust for noncompliance in one treatment arm to ad-
justing for noncompliance in two treatment arms, we will use a Bayesian approach to apply
principal stratification using the Roy et al. [30] model reviewed above for survival data but
which was originally proposed for binary data. Specifically we perform a comprehensive model
selection to obtain arm-specific optimal predictors of compliance and develop a causal model
linking the two marginal models from which we obtain causal effects for each stratum.
V. Application to the Esprit study
ITT analysis of the Esprit data showed no statistical difference between HRT and placebo
treatment with hazard ratio results (HR=exp(ψˆ)=0.795, p-value=0.335, 95%CI : 0.498, 1.268)
suggesting a beneficial effect of HRT over placebo with respect to death. However, the ITT
analysis took no account of compliance data. The rate of observed compliance was higher in
the placebo (63%) arm compared to the HRT (42%) treatment arm which may be attributed to
noncompliance as a result of possible unpleasant symptoms like bleeding. Utilizing compliance
data, we consider two outcomes (all-cause mortality and myocardial reinfarction) for causal
analysis using the methods described in the previous section.
When applying the Roy et al. [30] method for survival data, we use relative risks to
approximate hazard ratios. This is justifiable for our analysis given that under short follow-up
times (monthly) and small event rates conditions (death and myocardial reinfarctions), relative
risk has been shown to be an algebraic approximation of hazard ratio, i.e. exp(
¯ˆ
ψ) ∼= ˜ˆτ [36].
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V.1. Predicting compliance in each arm
In predicting compliance for each arm, we first choose a full (saturated) model consisting of
all potential predictors of compliance to treatment allocation on the basis of both clinical and
statistical plausibility. In addition we consider penalized maximum likelihood estimation regres-
sion versions of this (saturated) model and also Lasso (Least Absolute Shrinkage and Selection
Operator) model obtained by the method which performs the twin tasks of parameter shrink-
age and model selection [38]. To evaluate the predictive performance of the selected models,
we used calibration slope, percentage of optimism and calculated discrimination’s concordance
c-statistics from the reported Somers Dxy statistics. These validation measures will be recorded
for each individual arm in five models:
(i) Original saturated model with all the 9 predictors without any selection:
logit(µj) = γ0 + γ1Hysterectomy + γ2Smoking status + γ3Social-class+
γ4Age + γ5CVD Risks + γ6Diabetes + γ7Fracture + γ8Alcohol + γ9HRT,
where µ is the probability of compliance with treatment (placebo/HRT) allocation and
histories of hysterectomy, cerebrovascular disease (CVD) risks, diabetes, fracture, alcohol,
HRT use together with smoking status are taken as binary 0/1 predictors.
(ii) Reduced model obtained from (i) above by stepwise backward elimination procedures using
Akaike information criterion (AIC) stopping rule and 0.10 significance level for a variable
to be retained in a model.
(iii) Model fitted with the retained predictors in reduced model (ii) above but the predictors
assumed pre-specified (following suggestion by Harrell et al. [14]).
(iv) Intermediate model composed of 6 variables constructed using penalized maximum likeli-
hood estimation with modified AIC (χ2>2df).
(v) Least Absolute Shrinkage and Selection Operator (Lasso) model selection from the original
(i) above.
V.2. Validation: evaluating performance of selected models
We used enhanced bootstrap on all aspects of models development (selection and estimation
procedures) to revalidate on samples taken with replacement from the whole sample and apply
on the five models specified above. The reduced model was obtained from the original model
using stepwise backward elimination procedures using AIC stopping rule and 0.10 significance
level for retaining a predictor in a model. The variables selected for the reduced model were
consistently (90%) selected across bootstrap resamples. These were the same predictors deemed
important by the backward elimination algorithm.
Table 1 provide results showing the performance of the 5 prediction models in terms of
validation indices outlined earlier (see Section IV.1). The saturated (original) model consisting
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Table 1. Validation performance of 5 models in terms of calibration, concordance
and optimism (Section IV.1)
Calibration Optimism Concordance
Model Selected predictors slope (%) c-statistics
(i) Original
HRT 0.818 6.1 0.639
Placebo 0.671 8.6 0.573
(ii) Reduced
HRT (hyst+smk+CVD) 0.827 5.8 0.620
Placebo (hyst+smk+alc) 0.667 8.1 0.566
(iii) Reduced†
HRT (hyst+smk+CVD) 0.961 1.4 0.642
Placebo (hyst+smk+alc) 0.950 2.0 0.597
(iv) Intermediate
(6 predictors)
HRT 0.879 4.1 0.636
Placebo 0.766 6.0 0.580
(v) Lasso
HRT (hyst+smk+age+CVD) 0.935 2.3 0.647
Placebo (hyst+smk+alc) 0.925 2.3 0.595
hyst≡hysterectomy; smk≡ smoking status; alc≡alcohol; CVD≡cerebrovascular disease; †model assumed pre-specified
of 9 predictors produced better predictions of compliance to HRT than placebo. Here predicting
compliance to HRT and placebo, the original models would be overfitted by 18% and 33%
respectively. Also these models would be optimistic by 6% and 9% respectively in predicting
compliance to HRT and placebo. We note that although the observed rates of compliance for
placebo were higher than for HRT, the relatively ‘poor’ performance of the former compared to
the later predictive models may be attributed to poor quality of compliance data owing to the
common practice to monitor compliance with active treatment more accurately than placebo
treatment.
Compared to saturated model, the reduced model would perform relatively better in
predicting compliance to HRT compared to predicting placebo: specifically the reduced model
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predicting compliance to HRT would perform better at distinguishing compliers from non-
compliers (concordance c = 0.620) than the reduced model predicting compliance to placebo
(c= 0.566). Reduced models predicting compliance to placebo would be more optimistic (8%)
than those predicting compliance to HRT (6%). Predictions for compliance to HRT using the
reduced model would be equally well calibrated (slope = 0.83) compared to predictions from
the original full model (slope=0.82). As expected, the model with 3 predictors if assumed pre-
specified performed ‘best’ in terms of both calibration and discrimination among the 5 models
considered in predicting compliance to both HRT and placebo. These models also produced least
optimistic fits for predicting compliance to both arms. Specifically predictions of compliance
to both HRT and placebo using the 3 predictors assumed pre-specified were almost perfectly
calibrated (0.96 and 0.95) and least optimistic (1% and 2%).
Validation of the model with 6 predictors showed adequate performance with intermedi-
ate measures between the saturated models composed of 9 predictors and the Lasso models. We
observe that predictions of compliance to both HRT and placebo using the intermediate model
performed relatively ‘better’ than both predictions of compliance using the reduced model. For
example, predictions of compliance to placebo using the intermediate model is now equally op-
timistic (6%) as predictions of compliance to HRT using the reduced model, a result which may
make the assumption of ‘no preference to one treatment over the other’ (extended monotonicity)
plausible for the Esprit study.
Besides the reduced model fitted with predictors if assumed pre-specified, Lasso models
produced the best calibrated and discriminative models predictive of compliance to both HRT
and placebo (Table 1, lower panel). Predictions of compliance to both HRT and placebo using
the Lasso models were the least optimistic (2%) and almost perfectly calibrated (slope=0.93).
Although the Lasso prediction models performed ‘best’ compared to predictions from the other
four models, we note that the method uses the same tuning parameter for all coefficients. The
drawback of shrinking all coefficients by a constant, even for those non-zero coefficients, may
result in suboptimal choice of covariates with the potential to exclude potential predictors,
i.e. data wastage. Moreover, Lasso is known to fail efficient model selection in the presence of
correlated variable where it tends to select one variable from a group and ignore the others [45].
Overall, the intermediate models provided substantially improved predictions of compliance to
both HRT and placebo in terms of calibration and optimism without affecting the capability
to discriminate between compliers and non-compliers.
Table 2 provides estimated median compliance proportion for each of the four strata
for both all-cause mortality and myocardial reinfarction outcomes. On average, the estimated
median probabilities of compliance was higher among those patients allocated to placebo for
both all-cause mortality (myocardial reinfarction) outcomes (¯ˆµ0(x)=0.567 (0.565)) compared to
Imhotep Proc.
14 Lang’o Odondi
Table 2. Median compliance proportion per principal stratum for different
values of φ
Stratum Outcome: All-cause mortality Outcome: Reinfarction
φ φ
0 0.2 0.5 0.8 1 0 0.2 0.5 0.8 1
µˆ11(x) 0.264 0.296 0.353 0.406 0.460 0.266 0.303 0.359 0.417 0.456
µˆ01(x) 0.197 0.165 0.105 0.047 0 0.200 0.164 0.111 0.059 0.023
µˆ10(x) 0.303 0.262 0.211 0.155 0.105 0.300 0.263 0.206 0.142 0.102
µˆ00(x) 0.236 0.277 0.330 0.391 0.435 0.235 0.270 0.325 0.382 0.419
those on HRT tablets (¯ˆµ1(x)=0.461 (0.470)), i.e. the ratio U(x)=min{1, ¯ˆµ1(x)¯ˆµ0(x)}=0.795 (0.810).
We note a likelihood that a higher prevalence (proportion) of placebo compliance compared to
HRT may be a limitation of the model to effectively evaluate active HRT efficacy.
For all the four strata at mild value of sensitivity parameter (φ=0.2), the group with the
highest prevalence was patients who would comply with either treatment (¯ˆµ11 =0.296 (0.303))
and the group with the lowest prevalence is those who would only comply with HRT tablets
(¯ˆµ01 = 0.165 (0.164)). The median proportion of compliance among those patients who would
comply with placebo only and those who would not comply with either treatment allocation
were ¯ˆµ10 = 0.262 (0.263) and ¯ˆµ00 = 0.277 (0.270) respectively. Overall the estimated rates of
potential compliance were generally similar in each stratum for a given value of φ (except for
perfect correlation φ= 1). The apparent independence between the potential compliance rates
and outcome may be an indication of the plausibility of conditional compliance assumption
with respect to the Esprit data.
V.3. Causal risk ratio inference
We estimated the causal risk ratio parameters τij (Eq. 9) in a Bayesian setting using non-
informative priors for all log odds ratio parameters γj for potential predictors of compli-
ance. We specified uniform (0, 1) priors for the piS=sZ (pii, i = 1, . . . , 7) parameters, z = 0, 1,
S=(0,0),(1,0),(0,1),(1,1) and set the sensitivity parameter φ = 0, 0.2, 0.5 and 0.8. The choice
of φ were motivated by the need to explore all possible compliance behaviours including con-
ditional independence (φ = 0) and almost-perfect correlation (φ = 0.8). We ran three chains:
null starting values for chain one, mean and median values from a trial run for chains two and
three respectively. For convergence assessment, we ran simulation for 101, 000 iterations for
each of the three chains and excluded the first 1, 000 as burn-in. Posterior median relative risks
provided Bayesian point estimates for each stratum.
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Table 3. Causal risk ratio estimates (means of median posterior relative risks) for
mortality and reinfarction (mean median 95% CI) for each stratum for different values
of φ: (a) All-cause mortality (b) Myocardial reinfarction.
Compliance with Compliance with Compliance with
both HRT and placebo HRT only placebo only
φ pˆi2(pi
s=(1,1)
1 ) pˆi6(pi
s=(1,1)
0 ) pˆi1(pi
s=(0,1)
1 ) pˆi7(pi
s=(0,1)
0 ) pˆi4(pi
s=(1,0)
1 ) pˆi5(pi
s=(1,0)
0 )
(a)
0 0.011 0.012 0.053 0.099 0.051 0.055
τ11 =0.941 (0.026,34.349) τ01 =0.534 (0.101, 1.347) τ10 =0.933 (0.340,3.0129)
0.2 0.011 0.012 0.063 0.118 0.056 0.060
τ11 =0.867 (0.023,31.489) τ01 =0.533 (0.083,1.522) τ10 =0.938 (0.267,4.038)
0.5 0.011 0.012 0.092 0.168 0.064 0.073
τ11 =0.878 (0.025,30.539) τ01 =0.533 (0.068,2.310) τ10 =0.874 (0.126,5.702)
0.8 0.012 0.012 0.179 0.243 0.053 0.097
τ11 =0.974 (0.032,30.698) τ01 =0.723 (0.065,10.399) τ10 =0.560 (0.024,5.423)
(b)
0 0.012 0.021 0.106 0.143 0.094 0.107
τ11 =0.561 (0.061,19.989) τ01 =0.733 (0.293,1.406) τ10 =0.881 (0.474,2.182)
0.2 0.010 0.026 0.130 0.172 0.105 0.113
τ11 =0.397 (0.011,13.839) τ01 =0.752 (0.301,1.561) τ10 =0.932 (0.448,3.804)
0.5 0.008 0.044 0.200 0.244 0.125 0.109
τ11 =0.204 (0.006,5.479) τ01 =0.835 (0.432,2.881) τ10 =1.138 (0.351,17.590)
0.8 0.008 0.069 0.419 0.256 0.119 0.059
τ11 =0.121 (0.004,1.186) τ01 =1.594 (0.465,45.238) τ10 =1.905 (0.100,69.149)
aAll-cause mortality; bMyocardial reinfarction
Table 3 provide causal risk ratio estimates (Bayesian principal effects) obtained from
mean posterior median relative risks for each stratum and corresponding mean 95% credible
intervals for different values of sensitivity parameter φ. Here a posterior relative risk τ was
obtained as the ratio of two probabilities of experiencing an event due to compliance with one
treatment allocation relative to another in a stratum. Most of results (not all) show posterior
median relative risks of less than one for all values of φ which indicates lower risks for mortality
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and myocardial reinfarction for those women randomized to HRT who would be highly compli-
ant with their treatment allocation. A primary interest is the quantity τ01 =[pi
S=(0,1)
1 ][pi
S=(0,1)
0 ]
−1,
i.e. the posterior (causal) relative risk for mortality/reinfarction among the subgroup who would
comply with HRT treatment only. The results shows that the mean median 95% credible inter-
vals widened with increase in φ values, an indication of less correlation between HRT treatment
and placebo compliances. Overall, the results indicated that HRT tablets reduced risks for
myocardial reinfarction more than the reduction in risks for all-cause mortality.
For a mild correlation value (φ= 0.2), the results suggest that compliance with HRT
tablets only would substantially reduce the risk of death by about 47%, i.e. causal risk ratio
τ01 = 0.533, 95% CI : 0.083, 1.522. Also for this value of sensitivity parameter, the results
suggest that compliance with HRT treatment compared to taking placebo among those who
would comply with either treatment reduced the risk for all-cause mortality by 13%, i.e. causal
risk ratio τ11 =0.867, 95% CI : 0.023, 31.489. However, compliance with placebo treatment only
would marginally reduce the risk of death by about 6%, i.e. causal risk ratio τ01 =0.938, 95% CI :
0.267, 4.038. In general we note that compliance with HRT treatment only consistently suggested
reduction of risk for death at all sensitivity parameter values φ. For example, when φ=0.8, while
compliance with HRT treatment compared to taking placebo among those who would comply
with either treatment would essentially have no effect (τ11 = 0.974, 95% CI : 0.032, 30.698),
compliance with placebo treatment only would reduce the risk of death by about 44%, i.e.
causal risk ratio τ10 =0.560, 95% CI : 0.024, 5.423.
The size of causal (principal) effects varied according to the value of sensitivity param-
eter. Risks for myocardial reinfarction among those who would comply with placebo treatment
only increased with increase in the value of sensitivity parameter φ. On the other hand results
show reduction in risks for myocardial reinfarction among those who would comply with either
placebo or HRT treatment as the value of φ increased. As expected the risks for both death
and myocardial reinfarction outcomes were higher among those who would comply with placebo
only compared to those who would comply with HRT only for any chosen value of the sensitivity
parameter φ.
V.4. Sensitivity analysis
As outlined in assumptions (Section III), application of the Roy et al. [30] method is premised
on plausibility of the crucial, but untestable, conditional compliance assumption which posits
that the potential outcome is independent of the set of covariates predictive of treatment com-
pliance given a compliance type and treatment assignment. Hence the task of selecting suitable
predictors of treatment compliance constitutes an integral part of ensuring plausibility of this
assumption. A sensitivity analysis using different models (i.e sets of predictors) may be used to
assess how the causal estimates depend on departures from this crucial assumption [35].
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Table 4. Sensitivity analysis using 3, 6 and 9 predictors of compliance: Causal risk
ratio (median 95% CI)
All-cause mortality Myocardial reinfarction
φ Comply HRT Comply Comply Comply HRT Comply Comply
and placebo HRT only placebo only and placebo HRT only placebo only
A
0 1.126 0.546 0.872 0.539 0.739 0.874
(0.030,44.588) (0.106,1.417) (0.281,2.260) (0.014,19.650) (0.296,1.643) (0.462,2.522)
0.2 1.169 0.543 0.833 0.419 0.759 0.904
(0.031,42.058) (0.088,1.633) (0.210,2.428) (0.012,14.459) (0.298,1.839) (0.419,3.684)
0.5 1.247 0.590 0.716 0.250 0.839 1.004
(0.036,41.790) (0.070,3.136) (0.067,2.316) (0.007,6.184) (0.326,4.006) (0.248,9.907)
0.8 1.460 0.854 0.315 0.175 1.772 0.857
(0.050,44.267) (0.068,14.310) (0.012,1.769) (0.006,1.862) (0.447,52.647) (0.030,40.108)
B (τ11) (τ01) (τ10) (τ11) (τ01) (τ10)
0 0.941 0.534 0.933 0.561 0.733 0.881
(0.026,34.349) (0.101,1.347) (0.340,3.012) (0.061,19.989) (0.293,1.406) (0.474,2.182)
0.2 0.867 0.533 0.938 0.397 0.752 0.932
(0.023,31.489) (0.083,1.522) (0.267,4.038) (0.011,13.839) (0.301,1.561) (0.448,3.804)
0.5 0.878 0.533 0.874 0.204 0.835 1.138
(0.025,30.539) (0.068,2.310) (0.126,5.702) (0.006,5.479) (0.342,2.881) (0.351,17.590)
0.8 0.974 0.723 0.560 0.121 1.594 1.905
(0.032,30.698) (0.065,10.399) (0.024,5.423) (0.004,1.186) (0.465,45.238) (0.100,69.149)
C
0 1.264 0.533 0.889 0.707 0.737 0.841
(0.032,47.799) (0.102,1.323) (0.331,2.161) (0.018,26.389) (0.306,1.396) (0.455,1.702)
0.2 1.341 0.530 0.859 0.562 0.748 0.859
(0.035,47.004) (0.081,1.523) (0.254,2.151) (0.014,21.870) (0.288,1.575) (0.427,2.243)
0.5 1.413 0.553 0.782 0.356 0.810 0.900
(0.038,49.229) (0.065,2.290) (0.112,2.268) (0.010,10.390) (0.330,2.621) (0.296,4.480)
0.8 1.707 0.706 0.463 0.214 1.374 0.812
(0.055,49.708) (0.056,9.777) (0.022,1.856) (0.007,3.491) (0.423,30.800) (0.043,17.929)
Model comprising A3 (Lasso); B6 (Intermediate) and C9 (Saturated) predictors of compliance
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Table 4 show results in terms of causal relative risks for models predicting compliance
using three sets of predictors considered earlier: using 3, 6 and 9 predictors from Lasso, interme-
diate and all plausible predictors respectively. For mild values of sensitivity parameters, model
selection using penalized maximum procedures (6 predictors) produced ‘best’ causal risk ratio
estimates showing reduction of risks for both all-cause mortality and myocardial reinfarction.
Specifically HRT treatment was consistently effective (reduced risks) among those who would
comply with HRT only (τ01). The efficacy corresponding to this stratum was not dependent
on the chosen value of sensitivity parameter. On the other hand the causal risk ratio estimates
using 3 and 9 sets of predictors were comparable for all strata considered. In general, given a set
of predictors, the results show same trend in principal effects with respect to change in magni-
tude of the sensitivity parameter φ for both outcomes (mortality and myocardial reinfarction).
Surprisingly these results using 3 and 9 predictors of compliance now suggested harmful effects
(increased risks) of HRT treatment relative to placebo among those who would comply with
either treatment.
Results from the sensitivity analysis above (Table 4) may be a useful demonstration of
the phenomenon that causal (principal) effects are dependent on the choice of covariates pre-
dicting compliance. This may be an indication that the advantages of classical model selection
are transferable to the Roy et al. [30] method via use of optimal marginal compliance models,
i.e. comprehensive model selection may be useful in providing optimal predictors of compliance
to enrich principal stratification. However, we note that while selecting plausible predictors of
compliance is an integral component of the method, model selection only acts as an interme-
diate step that provides covariates for marginal compliance prediction models which are then
joined into a causal model using the crucial but unknown sensitivity parameter.
In general we observe from results in both Tables 3 and 4 that for a given stratum
and set of selected covariates predicting compliance, the change in resulting causal risk ratio
estimates were more pronounced for the reinfarction compared to all-cause mortality outcome.
This apparent interaction of outcome with sensitivity parameter φ may be attributed to fea-
tures of the two different outcomes. A possible explanation may be the fact that the choice of
optimal predictors of compliance to make the conditional compliance assumption (f) valid might
depend on outcome (death/reinfarction). Such an association may make conditional prediction
assumption questionable for the Esprit data especially with regard to history of hysterectomy
and cerebrovascular risks which are likely to be associated with better treatment compliance
and subsequently favourable outcome.
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VI. Discussion
By using optimal predictors of treatment compliance at mild values of the sensitivity parameter
φ, compliance with HRT tablets showed reduction in risks for both all-cause mortality and
myocardial reinfarction. Compliance with HRT treatment compared to taking placebo among
those who would comply with either treatment also indicated beneficial effects in reducing risks
for both outcomes. Compliance with HRT treatment suggested beneficial effects compared to
placebo for all other values of φ among the subgroup who would comply with HRT treatment
only and those who would comply with either treatment allocation. However, causal risk ratios
estimating efficacy of compliance to either treatment (τ11) had relatively wider mean 95%
credible intervals compared to estimates for efficacy of compliance with HRT only (τ01) or
placebo only (τ10). In general, the risk for myocardial reinfarction reduced with increase in the
value of sensitivity parameter φ among those women who would comply with either treatment.
On the other hand the risk of myocardial reinfarction increased with increase in φ among those
who would comply with placebo treatment only. Overall as expected, for any chosen value of
the sensitivity parameter φ, the risks for both death and myocardial reinfarction were higher
among those who would comply with placebo only compared to those who would comply with
HRT only.
The variation in the HRT efficacy estimates from the Roy et al. [30] model may be
an indication of difference in compliance behaviour between those allocated to placebo and
HRT treatment. By adjusting for noncompliance in both arms, the Roy et al. method perhaps
accounts for potential correlation between compliance behaviours in respective arms through
the chosen value of the sensitivity parameter which implicitly makes the results depend on
φ. The fact that the results vary a lot with φ and yet we do not know its value suggests
benefits of HRT treatment among those who comply when allocated it, i.e. strong monotonicity
assumption (strong correlation in compliance behaviour between the two arms). Finally our
analyses with flat priors may be considered adequate given the likelihood of a typical trial data
to dominate such priors in addition to the fact that randomized trials are principally designed
to be conclusive [16].
Noncompliance with treatment assignment in both arms of a clinical trial is likely to
complicate efficacy estimation. Here the ITT provide a biased estimator for the true causal esti-
mate even under homogeneous treatment effects assumption. Extending and applying the Roy
et al. model to survival data (Esprit study) may be suitable by utilizing key covariates predictive
of arm-specific compliance models to develop causal models linking the two marginal models.
The resulting principal effects provides efficacy estimates for the different subgroups defined by
compliance types. The method performed relatively ‘better’ than specialist randomization-based
causal methods adjusting for noncompliance in one treatment arm only [25]. Simulation studies
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indicated satisfactory performance of the method however, the results were heavily dependent
on the choice of sensitivity parameters and hence may not be recommended in the presence
of known heterogeneous treatment effects which produced large bias and wider corresponding
95% credible intervals. As a result, the method may only be recommended in the presence of
sufficient information about compliance behaviours in respective arms.
Model selection in regression may be correctly considered as one of the most significant
challenges in modern statistics [17]. Hitherto this challenge has not been extended to include
prediction of compliance with treatment assignment in causal modelling. There are presently
limited studies integrating model selection for compliance prediction in causal inference. While
principal stratification has independently been demonstrated to provide better alternative iden-
tification strategies compared to selection model [23], integrating the two strategies may produce
even more flexible models under relaxed assumptions. A record of plausible predictors of com-
pliance can be used to effectively address identification problem of causal estimands by reducing
bias and relaxing the implicit assumptions [20]. From a clinical perspective, knowledge about
predictors of compliance may be a valuable tool to inform treatment decisions. As a result,
there is need to adopt comprehensive model selection methods for accurate prediction (of com-
pliance). After model selection, there is further need to use suitable validation indices (e.g.
optimism, calibration and discrimination indices) to evaluate performance of selected models.
With potentially many recorded baseline covariates, using penalized regression techniques may
be recommended for building compliance prediction models.
The merits of standard model selection procedures are transferable to the principal
stratification method adjusting for noncompliance in two treatment arms by linking the respec-
tive optimal marginal compliance models into an association model [26]. However, application
of the method is premised on the plausibility of a defining assumption that potential outcome is
independent of the set of covariates predicting treatment compliance for a given stratum. This
assumption may be questionable for the Esprit data especially with regard to history of hysterec-
tomy and cerebrovascular risks which potentially have a higher likelihood to be associated with
treatment compliance leading to possible efficacy. For example, while the unpleasant experience
of bleeding may affect treatment compliance negatively, those with history of cerebrovascular
risks may comply with their treatment allocation with a hope to derive potential protective
benefits. Further sensitivity analysis on the departure of conditional prediction assumption im-
plicit in the Roy et al. model may be conducted using alternative methods which incorporate
less stringent assumptions. For example, by adopting the Bayesian framework introduced by
Long et al. [21] to model the principal compliances directly in multitreatment arms and for
more general outcomes by treating the principal compliance status as missing data instead of
joining them with a user-defined sensitivity parameter φ.
Imhotep Proc.
Vol. 1 (2014) REFERENCES 21
Although principal stratification provides a powerful framework which is extendible to
analyse complex surrogate outcomes like ‘truncation by death’ where death occurs before a
primary outcome of interest is recorded hence resulting in censored records [31], the method’s
application and usefulness may be limited to intermediates with fewer categories (e.g. binary)
[40]. Although the all-or-nothing compliance suitably applied to the Esprit data, principal
stratification in general produce inconsistent causal estimate for a truly continuous stratification
variable but which has been coarsened for analysis [28]. As a result, policy informed by analysis
based on principal stratification should be implemented with caution owing to the fact that the
principal strata themselves remain unidentified.
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